BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21166510)

  • 21. Gynecologic malignancies.
    Schilder RJ; Scher RM; Young RC
    Cancer Chemother Biol Response Modif; 1993; 14():530-56. PubMed ID: 8312118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical management of recurrent ovarian cancer.
    Leitao MM; Chi DS
    Semin Oncol; 2009 Apr; 36(2):106-11. PubMed ID: 19332245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the management of epithelial ovarian cancer.
    Berkenblit A; Cannistra SA
    J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Locoregional recurrence of ovarian cancer: the place of surgery].
    Classe JM; Catala L; Marchal F; Ferron G; Dravet F; Pioud R; Descamps P
    Bull Cancer; 2004 Nov; 91(11):827-32. PubMed ID: 15582885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
    Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
    Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Surgical therapy of ovarian carcinoma].
    Sevelda P
    Wien Med Wochenschr; 1996; 146(1-2):18-22. PubMed ID: 8835491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma].
    Zang R; Zhang Z; Cai S
    Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
    Lin H; Changchien CC
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?
    Munkarah A
    Nat Clin Pract Oncol; 2005 Apr; 2(4):188-9. PubMed ID: 16264930
    [No Abstract]   [Full Text] [Related]  

  • 31. Surgery for recurrent ovarian cancer.
    Rose PG
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):17-23. PubMed ID: 10952122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of secondary cytoreductive surgery for recurrent ovarian cancer.
    Güngör M; Ortaç F; Arvas M; Kösebay D; Sönmezer M; Köse K
    Gynecol Oncol; 2005 Apr; 97(1):74-9. PubMed ID: 15790440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent surgical management of ovarian cancer.
    Khoury-Collado F; Chi DS
    J Obstet Gynaecol Res; 2011 May; 37(5):379-82. PubMed ID: 21463433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
    Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
    Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical treatment of epithelial ovarian cancer.
    González-Martín AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.
    Fagotti A; Paris I; Grimolizzi F; Fanfani F; Vizzielli G; Naldini A; Scambia G
    Gynecol Oncol; 2009 Jun; 113(3):335-40. PubMed ID: 19345401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Latest information in the diagnoses of ovarian carcinoma].
    Isonishi S
    Gan To Kagaku Ryoho; 2002 Aug; 29(8):1351-7. PubMed ID: 12214460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
    Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
    Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.